 |
| Serrapeptidase |
| Research studies show that Serrapeptidase relieves inflammation, reduces swelling, and thins the thick mucus often found in sinusitis, and so it makes the pain of sinusitis greatly reduced. It is not an antibiotic or antifungal compound, however, so bacterial or fungal infections that can be the basis for sinusitis will not be cured. It will definitely relieve your symptoms, making you feel better. However, you should still find out what is causing your sinus problems so you can find the appropriate treatment to stop the seemingly endless cycle. |
|
Serratiopeptidase is an enzyme derived from a bacteria from the genus
serratia. This enzyme has several different spellings:
serratiapeptidase, serratia peptidase, serrapeptidase. Serratiopeptidase is supposed to be particularly helpful with arthritis or other pain (inflammation). A number of products featuring serratiopeptidase have been on the market for quite a while now with a good reputation of success. Many clinical studies verify the effectiveness of serratiopeptidase. It is said to have even fewer side-effects or adjustments than other enzymes. |
|
Clinical research studies have found that serrapeptidase prompts
anti-inflammatory activity, anti-edemic activity (the lessening of
fluid retention), and fibrinolytic activity (the dissolution of
protein buildups). Both in vitro and in vivo studies have revealed
that its specific anti-inflammatory effects are far superior to that
of other proteolytic enzymes. Serrapeptidase also alters the elasticity and viscosity of the dense mucus produced in people with respiratory conditions. People with sinusitis, bronchitis, asthma, and pulmonary diseases show much improved structure and function of the mucus after taking serrapeptidase. Serrapeptidase has been found to be effective against arthritis, ear nose and throat conditions, injury-related swelling, varicose veins and other vascular conditions, and has been used to dissolve arterial plaque. The renowned internist Dr. Hans Nieper, well known for his work with proteolytic enzymes, referred to serrapeptidase as "the miracle enzyme". |
| Ear, Nose, and Throat Conditions |
| A study of 193 patients with acute or chronic ear, nose and throat pathologies (including laryngitis). After 3-4 days, patients taking serrapeptidase experienced a significant reduction in pain, secretion and other symptoms. Improvement was excellent or good for 97.3% of the serrapeptidase patients, compared with only 21.9% of the placebo patients.(1) |
| A study of 193 patients with acute or chronic ear, nose and throat pathologies (including laryngitis). After 3-4 days, patients taking serrapeptidase experienced a significant reduction in pain, secretion and other symptoms. Improvement was excellent or good for 97.3% of the serrapeptidase patients, compared with only 21.9% of the placebo patients.(1) |
| Respiratory Conditions |
| In respiratory diseases characterized by increased production of dense mucus, serrapeptidase alters mucus elasticity and results in a considerable reduction in viscosity, confirming its efficacy as a mucolytic agent.(2,3,4) A Japanese study of patients with chronic airway diseases found that treatment with serrapeptidase caused symptoms to significantly decrease, and exerted a beneficial effect on mucus clearance.(5) A double-blind study of 174 patients found the degree of swelling in serrapeptidase-treated patients was consistently and significantly less than in the placebo group, without side effects.(6) |
| References: |
|
1. Mazzone A, et al. Evaluation of serratia peptidase in acute or
chronic inflammation of otorhinolaryngology pathology: a multicentre,
double-blind, randomized trial versus placebo. J Int Med Res. 1990;
18(5):379-88. 2. Tomoda K, and Miyatam K. Some information on the composition of trachael secretions before and after the administration of Danzen. Exper Ther. 1972; 477:9-16. 3. Marriott C. Modification in the rheological properties of mucus by drugs. Adv Exp Med Biol. 1982; 144:75-84. 4. Carratu L, et al. Physico-chemical and rheological research on mucolytic activity of serratio-peptidase in chronic broncho-pneumopathies. Therapeutic Res. Dec 1980; 937-951. 5. Nakamura S, et al. Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology Vol 8 #3, Sept 2003, p.316-320 doi:10.1046/j.1440-1843.2003.00482. 6. Tachibana M, et al. A muti-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica; 1984; 3(8); 526-30. |
|
© Copyright 2002 - 2010 Advanced Scientific Health All Rights Reserved. For product and shipping issues ashnow@bellsouth.net 770-952-7991 For all others support@ashnow.com 801-274-3767 Phone Support: Monday - Friday 10AM - 4PM MST |
|
|
|
